Cases

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE STEPHEN M. SCIANNELLA, individually ) and on behalf of all others similarly situated, ) ) Plaintiff, ) ) v. ) C.A. No. 2023-0125-PAF ) ASTRAZENECA UK LIMITED, ) ASTRAZ

Appellate Case: 24-4114 Document: 49-1 Date Filed: 07/23/2026 Page: 1 FILED United States Court of Appeals PUBLISH Tenth Circuit UNITED STATES COURT OF APPEALS July 23, 2026

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE STEPHEN M. SCIANNELLA, individually ) and on behalf of all others similarly situated, ) ) Plaintiff, ) ) v. ) C.A. No. 2023-0125-PAF ) ASTRAZENECA UK LIMITED, ) ASTRAZ

LOURIE, Circuit Judge. Astrazeneca, AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and Astrazeneca LP (collectively “Astra”) appeal from the decision of the U.S. District Court for the Southern District of New York, following a bench trial, finding noninfringement of U.S. Patents 4,786,505 (“the '505 patent”) and 4,853,230 (“the '230 patent”) by Mylan Laboratories, Inc., Mylan Pharmaceuticals, Incorporated (collectively “M

603 F.Supp.2d 596 (2009) ASTRAZENECA AB, Aktiebolaget Hassle and AstraZeneca LP, KBI Inc. and KBI-E, Inc., Plaintiffs-Counterclaim Defendants, v. DR. REDDY'S LABORATORIES, LTD., and Dr. Reddy's Laboratories, Inc., Defendants-Counterclaim Plaintiffs. No. 07 Civ. 6790 (CM)(GWG). United States District Court, S.D. New York. March 10, 2009.

Opinion & Order BARBARA S. JONES, District Judge. *387TABLE OF CONTENTS INTRODUCTION. CO CO o I. The Parties. CO CO o II. The Patents-In-Suit. 03 05 CO A. Patent Ownership. CO CO III. The Pleadings. CO CO A. Complaint Against Mylan/Esteve.

MARCUS, Circuit Judge: In this civil RICO case, plaintiffs seek to represent a class of customers claiming that Spirit Airlines, Inc. (“Spirit”) engaged in an elaborate criminal enterprise involving the use of mail and wire fraud. The complaint specifically alleged that Spirit portrayed its Passenger Usage Fee as a government-imposed or authorized fee

250 F.Supp.2d 506 (2003) ASTRAZENECA AB, et al., v. MUTUAL PHARMACEUTICAL CO., INC. Civil Action 00-4731. United States District Court, E.D. Pennsylvania. March 14, 2003. *507 Eric Kraeutler, John V. Gorman, Morgan, Lewis & Bockius, LLP, Philadelphia, PA, Errol B. Taylor, Amr 0. Aly, Lisa B. Baeurle, Fitzpatrick, Cella, Harpe

MARCUS, Circuit Judge: Plaintiffs commenced this civil suit against Spirit Airlines, Inc. (“Spirit”) under the Racketeer Influenced and Corrupt Organizations Act (RICO), 18 U.S.C. §§ 1961-68, alleging that Spirit conducted an enterprise by means of racketeering activity—here, two or more predicate acts of mail and wire fraud involving the concealment and misrepresentation of a

49 Cal.4th 758 (2010) 111 Cal. Rptr. 3d 666 233 P.3d 1066 JAMES CLAYWORTH et al., Plaintiffs and Appellants, v. PFIZER, INC., et al., Defendants and Respondents. No. S166435. Supreme Court of California. July 12, 2010. *761 Alioto Law Firm, Joseph M. Alioto, Joseph M. Alioto, Jr., T

Joseph F. Bataillon, Senior United States District Judge This matter is before the Court following plaintiff's presentation of its case at trial. At the end of plaintiff's case, the Court listened to motions and arguments from the parties. The Court determined that plaintiff C.R. Bard Inc. (hereinafter "Bard") had not presented sufficient evidence regarding its claims and, therefore, issued a judgment as a matter of law pursuant to

Case: 24-1324 Document: 51 Page: 1 Filed: 07/12/2024 United States Court of Appeals for the Federal Circuit ______________________ NATERA, INC., Plaintiff-Appellee v. NEOGENOMICS LABORATORIES, INC., Defendant-Appellant ______________________ 2024-1324, 2024-1409 ______________________ Appeals from the United State

Case: 24-1324 Document: 51 Page: 1 Filed: 07/12/2024 United States Court of Appeals for the Federal Circuit ______________________ NATERA, INC., Plaintiff-Appellee v. NEOGENOMICS LABORATORIES, INC., Defendant-Appellant ______________________ 2024-1324, 2024-1409 ______________________ Appeals from the United State

United States Court of Appeals For the First Circuit No. 22-1536 WILLIAM RIOS, Plaintiff, Appellant, v. CENTERRA GROUP LLC, Defendant, Appellee. APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF PUERTO RICO [Hon. Pedro A. Delgado-Hernández, U.S. District Judge]

Reyna, Circuit Judge. *1336 Alkem Laboratories Limited, Hikma Pharmaceuticals International Limited, and Hikma Pharmaceuticals USA Inc. appeal the judgment of the district court that

Case: 19-1756 Document: 72 Page: 1 Filed: 11/10/2020 United States Court of Appeals for the Federal Circuit ______________________ C R BARD INC., BARD PERIPHERAL VASCULAR, INC., Plaintiffs-Appellants v. ANGIODYNAMICS, INC., Defendant-Appellee ______________________ 2019-1756, 2019-1934 __________

PUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 19-6152 UNITED STATES OF AMERICA, Plaintiff - Appellee, v. JOHN DOE, Defendant - Appellant. Appeal from the United States District Court for the Eastern District of North Carolina, at Wilmington. James C. Dever III, District Judge. (7:11-cr-00085-D-1) Submi

OPINION BY Judge SIMPSON. I. Introduction This appeal involves a civil suit by the Commonwealth of Pennsylvania against the manufacturer of a drug, Risperdal, the cost of which is reimbursed through several Commonwealth agencies. The Commonwealth’s theory of recovery at trial was that the drug manufacturer, Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Janssen), fraudulently withheld informa

USCA11 Case: 19-10869 Date Filed: 04/22/2021 Page: 1 of 38 [PUBLISH] IN THE UNITED STATES COURT OF APPEALS FOR THE ELEVENTH CIRCUIT ________________________ No. 19-10869 ________________________ D.C. Docket No. 1:15-cv-00056-LAG TAMANCHIA MOORE,

CHAMBERLIN, JUSTICE, FOR THE COURT: ¶ 1. In 2005, the State of Mississippi filed suit against more than eighty prescription drug manufacturers alleging, among other things, that each committed common-law fraud and violations of the Mississippi Consumer Protection Act. The allegations, which will be more thoroughly discussed, focused on whether the prescription-drug manufacturers inflated reported prices, which caused the